Table 2 RDV administration, safety measures and other therapies

RDV administration

 Dose of RDV

 Duration of therapy (days) - median ± IQR (range)

  ≤ 5 days - n (%)

  > 5 days - n (%)

 Time from symptoms onset to administration (days) - median ± IQR (range)

 Time from pneumonia to administration (days) - median ± IQR (range)

4 ± 1 (1–10)

32 (78)

9 (22)

6 ± 3 (0–15)

2 ± 2 (0–8)

9

9

-

-

9

10

Safety evaluation of RDV administration

 AST pre-RDV (U/L, max value)– median ± IQR (range)

 AST post-RDV (U/L, max value)– median ± IQR (range)

 ALT pre-RDV (U/L, max value) - median ± IQR (range)

 ALT post-RDV (U/L, max value) - median ± IQR (range)

 Creatinine pre-RDV (mg/dl, max value) - median ± IQR (range)

 Creatinine post-RDV (mg/dl, max value) - median ± IQR (range)

 eGFR (ml/min, max value)* - median ± IQR (range)

 Ipertransaminasemia - n (%)

 Bradicardia - n (%)

 Rash - n (%)

 Renal insufficiency (according to eGFR) - n (%)

40 ± 47 (9–280)

43 ± 47 (19–164)

34 ± 70 (6–302)

54 ± 108 (6–350)

0.6 ± 0.3 (0.1–0.9)

0.6 ± 0.4 (0.1–0.9)

120 ± 91 (79–236)

14 (44)

2 (4)

3 (6)

0 (0)

13

18

13

18

13

16

21

18

0

0

21

Antibiotic therapy

 Macrolides - n (%)

  Azithromycin - n (%)

  Clarithromycin - n (%)

  Duration (days) - median ± IQR (range)

10 (24)

6 (15)

3 (7)

6.5 ± 5 (0–13)

8

9

9

-

 Other than macrolides** - n (%)

  Ceftriaxone or other cephalosporin - n (%)

  Piperacillin-tazobactam or tazobactam - n (%)

  Amoxicillin-clavulanate or other beta-lactam - n (%)

  Teicoplanin - n (%)

  Aminoglycosides - n (%)

  Fluoroquinolones - n (%)

  Linezolid - n (%)

  Meropenem - n (%)

  Metronidazole - n (%)

  Trimethoprim-sulfamethoxazole - n (%)

  Duration (days) - median ± IQR (range)

13 (34)

12 (32)

7 (18)

4 (11)

3 (8)

3 (8)

1 (3)

1 (3)

1 (3)

1 (3)

9 ± 11 (4–28)

12

12

12

12

12

12

12

12

12

12

-

Corticosteroid therapy

 Duration (days) - median ± IQR (range)

  Desametasone - n (%)

  Methylprednisolone - n (%)

  Prednisone - n (%)

9.5 ± 9 (3–36)

9 (27)

19 (58)

3 (9)

12

17

17

17

Other therapies

 Heparin - n (%)

  Duration (days) - median ± IQR (range)

 Monoclonal antibody - n (%)

  Duration (days) - median ± IQR (range)

 Hyperimmune plasma - n (%)

20 (63)

11 ± 20 (2–58)

3 (7)

2.5 ± / (1–4)

2 (8)

18

2

8

1

25